Table 1 Baseline characteristics of patients by the five-CpG-based classifier assessment set.
From: A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma
Characteristic | SYSU set ( n =168) | MCHC set ( n =284) | UTSW set ( n =243) | TCGA set ( n =298) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
No.of patients | Low risk (%) | High risk (%) | No.of patients | Low risk (%) | High risk (%) | No.of patients | Low risk (%) | High risk (%) | No.of patients | Low risk (%) | High risk (%) | |
Age (years) | ||||||||||||
<60 | 107 | 51 (48%) | 56 (52%) | 178 | 104 (58%) | 74 (42%) | 128 | 82 (64%) | 46 (36%) | 129 | 71 (55%) | 58 (45%) |
≥60 | 61 | 33 (54%) | 28 (46%) | 106 | 53 (50%) | 53 (50%) | 115 | 60 (52%) | 55 (48%) | 169 | 67 (40%) | 102 (60%) |
Sex | ||||||||||||
Male | 113 | 55 (49%) | 58 (51%) | 190 | 109 (57%) | 81 (43%) | 151 | 87 (58%) | 64 (42%) | 193 | 71 (37%) | 122 (63%) |
Female | 55 | 29 (53%) | 26 (47%) | 94 | 48 (51%) | 46 (49%) | 92 | 55 (60%) | 37 (40%) | 105 | 67 (64%) | 38 (36%) |
Race | ||||||||||||
Asian | 168 | 84 (50%) | 84 (50%) | 284 | 157 (55%) | 127 (45%) | 4 | 1 (25%) | 3 (75%) | 1 | 0 (0%) | 1 (100%) |
White | 0 | 0 | 183 | 104 (57%) | 79 (43%) | 264 | 120 (45%) | 144 (55%) | ||||
Black | 0 | 0 | 36 | 23 (64%) | 13 (36%) | 30 | 18 (60%) | 12 (40%) | ||||
Not available | 0 | 0 | 20 | 14 (70%) | 6 (30%) | 3 | 0 (0%) | 3 (100%) | ||||
Grade | ||||||||||||
G1 | 8 | 6 (75%) | 2 (25%) | 21 | 15 (71%) | 6 (29%) | 10 | 8 (80%) | 2 (20%) | 6 | 6 (100%) | 0 (0%) |
G2 | 87 | 42 (48%) | 45 (52%) | 134 | 80 (60%) | 54 (40%) | 128 | 84 (66%) | 44 (34%) | 123 | 75 (61%) | 48 (39%) |
G3 | 51 | 25 (49%) | 26 (51%) | 88 | 45 (51%) | 43 (49%) | 77 | 38 (49%) | 39 (51%) | 120 | 50 (42%) | 70 (58%) |
G4 | 22 | 11 (50%) | 11 (50%) | 41 | 17 (41%) | 24 (59%) | 28 | 12 (43%) | 16 (57%) | 49 | 7 (14%) | 42 (86%) |
Tumour size | ||||||||||||
<5 cm | 60 | 33 (55%) | 27 (45%) | 140 | 76 (54%) | 64 (46%) | 136 | 93 (68%) | 43 (32%) | 119 | 76 (64%) | 43 (36%) |
≥5 cm | 108 | 51 (47%) | 57 (53%) | 144 | 81 (56%) | 63 (44%) | 107 | 49 (46%) | 58 (54%) | 178 | 62 (35%) | 116 (65%) |
Not available | 0 | 0 | 0 | 1 | 0 (0%) | 1 (100%) | ||||||
Tumour necrosis | ||||||||||||
Absent | 104 | 56 (54%) | 48 (46%) | 189 | 102 (54%) | 87 (46%) | 164 | 103 (63%) | 61 (37%) | 138 | 71 (51%) | 67 (49%) |
Present | 64 | 28 (44%) | 36 (56%) | 95 | 55 (58%) | 40 (42%) | 70 | 32 (46%) | 38 (54%) | 160 | 67 (42%) | 93 (58%) |
Not available | 0 | 0 | 9 | 7 (78%) | 2 (22%) | 0 | ||||||
pT | ||||||||||||
T1 | 97 | 49 (51%) | 48 (49%) | 180 | 101 (56%) | 79 (44%) | 156 | 107 (69%) | 49 (31%) | 145 | 95 (66%) | 50 (34%) |
T2 | 30 | 15 (50%) | 15 (50%) | 54 | 27 (50%) | 27 (50%) | 30 | 10 (33%) | 20 (67%) | 38 | 18 (47%) | 20 (53%) |
T3 | 37 | 17 (46%) | 20 (54%) | 46 | 27 (59%) | 19 (41%) | 52 | 24 (46%) | 28 (54%) | 107 | 23 (21%) | 84 (79%) |
T4 | 4 | 3 (75%) | 1 (25%) | 4 | 2 (50%) | 2 (50%) | 5 | 1 (20%) | 4 (80%) | 8 | 2 (25%) | 6 (75%) |
pN | ||||||||||||
N0 | 152 | 78 (51%) | 74 (49%) | 267 | 151 (57%) | 116 (43%) | 226 | 134 (59%) | 92 (41%) | 129 | 62 (48%) | 67 (52%) |
N1 | 16 | 6 (37%) | 10 (63%) | 17 | 6 (35%) | 11 (65%) | 17 | 8 (47%) | 9 (53%) | 8 | 1 (12%) | 7 (88%) |
NX | 0 | 0 | 0 | 161 | 75 (47%) | 86 (53%) | ||||||
M | ||||||||||||
M0 | 163 | 83 (51%) | 80 (49%) | 274 | 150 (55%) | 124 (45%) | 221 | 136 (62%) | 85 (38%) | 244 | 125 (51%) | 119 (49%) |
M1 | 5 | 1 (20%) | 4 (80%) | 10 | 7 (70%) | 3 (30%) | 22 | 6 (27%) | 16 (73%) | 54 | 13 (24%) | 41 (76%) |
Stage (clinical) | ||||||||||||
Stage I | 91 | 45 (49%) | 46 (51%) | 171 | 96 (56%) | 75 (44%) | 155 | 107 (69%) | 48 (31%) | 141 | 95 (67%) | 46 (33%) |
Stage II | 27 | 15 (56%) | 12 (44%) | 48 | 24 (50%) | 24 (50%) | 25 | 9 (36%) | 16 (64%) | 28 | 15 (54%) | 13 (46%) |
Stage III | 36 | 17 (47%) | 19 (53%) | 43 | 28 (65%) | 15 (35%) | 39 | 20 (51%) | 19 (49%) | 73 | 15 (20%) | 58 (80%) |
Stage IV | 14 | 7 (50%) | 7 (50%) | 22 | 9 (41%) | 13 (59%) | 24 | 6 (25%) | 18 (75%) | 56 | 13 (23%) | 43 (77%) |
